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genetic polymorphisms could affect the treatment response and might 
be used as genetic marker of tumor response after radiation therapy.
Session M03: Molecular Predictors of EGFR TKIs
M03-01  Molecular Predictors of EGFR TKIs , Mon, Sept 3, 10:30 - 12:00
Molecular predictors of EGFR-TKIs
Mitsudomi, Tetsuya Kosaka, Takayuki Onozato, Ryoichi Matsuo, 
Keitaro Yatabe, Yasushi 
Aichi Cancer Center, Nagoya, Japan
Subsets of patients with non-small cell lung cancer (NSCLC) respond 
remarkably well to small molecule tyrosine kinase inhibitors (TKI) 
speciﬁc for epidermal growth factor receptor (EGFR) such as geﬁtinib 
or erlotinib. Those patients are typically of East Asian ethnicity, female 
gender, no history of smoking or those with adenocarcinoma. In 2004, 
it was found that NSCLC occurring in patients with above-mentioned 
characteristics frequently harbors activating mutations of the EGFR 
gene. Of note, EGFR mutation is a ﬁrst molecular alteration in NSCLC 
that is more frequent in never smoking patients. Our case-control study 
indicated that EGFR mutations occurred independent of smoking and 
apparent inverse relationship with smoking was due to dilution by 
tumors without EGFR mutations that increased with smoking history. 
In general, about 80% of NSCLCs with EGFR mutations respond to 
EGFR-TKIs, whereas some 10% of tumors without the mutations do 
so. Several investigators claim that EGFR gene copy number is more 
predictive of response or survival, although at least in our cohort, 
EGFR mutations were far better than copy number. In addition, various 
predictive markers have been reported to date. Those include expres-
sion of ligands for EGFR, change in other HER family genes including 
HER2 mutation or downstream molecules of EGFR pathway (e.g., 
KRAS mutation, AKT phosphorylation, PTEN expression, etc.). 
It is common for patients to show disease progression after presenting 
with an initial marked response to EGFR-TKIs. Secondary mutation 
occurring in exon 20 of the EGFR gene (T790M ) has been associated 
with the acquired resistance to EGFR-TKI. We were able to conﬁrm 
that 7/14 patients with acquired resistance after initial dramatic re-
sponse had T790M, but that no novel mutations were found. New class 
of TKIs that are able to overcome T790M are currently being devel-
oped. Very recently, Engelman et al. reported that ampliﬁcation of the 
MET gene is another mechanism of acquired resistance of EGFR-TKI 
through activation of HER3 signaling. It is known that some NSCLCs 
have T790M or MET ampliﬁcation even before EGFR-TKI therapy. 
Obviously, these NSCLC would require another treatment strategy.
Since all but one phase III trials have failed to show a survival advan-
tage of the treatment arm involving EGFR-TKIs, it appears mandatory 
to select patients by several of above-mentioned biomarkers. Through 
these efforts, it would be possible to individualize EGFR-TKI treatment 
for patients suffering from lung cancer.
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Worldwide, lung cancer is responsible for more than one million death 
per annum and is the leading cause of cancer mortality. Most patients 
with lung cancer are not cured and the overall 5-year survival rate is 
approximately 15%. Recent advances in the knowledge of cancer biol-
ogy led to the identiﬁcation of several potential molecular targets that 
play a key role in cancer development and progression. Selective tar-
geting of cancer cells based on their molecular phenotype can provide 
effective anti-cancer activity avoiding the commonly experienced side 
effects induced by chemotherapy. The new agents range from antibod-
ies that form complexes with antigens on the surface of the cancer cell 
to small molecules that have been engineered to block key enzymatic 
reaction. The interaction of the drug with its target inhibits pathways 
that are essential for cell proliferation or activates pathways that culmi-
nate in cancer cell apoptosis. So far, the dominant clinical trial strategy 
for patients with Non-Small-Cell Lung Cancer (NSCLC) has been to 
include a generic population of patients, with no selection based on 
biological criteria and, most importantly, with none or poor target as-
sessment. Although recent clinical trials in NSCLC have demonstrated 
survival improvement without a deﬁned biological endpoint, the hazard 
of continuing to perform clinical trials without any patient selection 
carries the risk of administering the wrong drug to the wrong patient 
and considering ineffective a drug that could dramatically improve the 
outcome of some patients, even if those are numerically small. 
The Epidermal Growth Factor Receptors (EGFRs) stand at the origin of 
a major signaling pathway involved in the growth of lung cancer. The 
EGFR superfamily includes four distinct closely related transmembrane 
receptors: EGFR/erbB-1, HER2/erbB-2, HER3/erbB-3, and HER4/
erbB-4. EGFR is normally found on the surface of epithelial cells and 
has been found to be commonly overexpressed in a variety of human 
malignancies. Different ligands can lead to EGFR activation and sub-
sequent signal transduction, including the epidermal growth factor, the 
transforming growth factor alpha and neuregulins. After ligand bind-
ing to the extracellular receptor domain, EGFR undergoes homo- or 
heterodimerization and autophosphorylation of its intracellular tyrosine 
kinase domain. These autophosphorylation events trigger a cascade of 
downstream signals, which ultimately result in an increase of cellular 
